News tagged "PLCO"
Preliminary applications for PLCO EEMS Round 21 will only be accepted from approximately December 1, 2015, through January 3, 2016. If you plan to submit an EEMS application this cycle, an approved preliminary application is required. Please note that this has changed from previous application cycles. Once your preliminary application has been approved, you will be notified and you will be able to continue and submit a full application. The deadline for full application submission is March 1, 2016.
Information is available regarding the PLCO trial and biospecimens.
Due to administrative factors and uncertainty in website development, the timeline for the release of the preliminary application and upcoming review cycle will be subject to changes. Please check CDAS frequently for an updated timeline. If you have any questions, please contact CDAS staff at cdas-eems@imsweb.com.
New PLCO cancer data added. Data version: may14.d052114
- New Inadequate FSG variables:
- The variables fsgin0/3/5/35 were removed from the colon person file.
- The new variable fsg_in was added to the screening file, and the variables fsg_in0/3/5/35 were added to the person file. See documentation for variable formats.
- New Hematopoetic Cancer Type variable:
- The variable hema_type was given a new format in the hema_prsn file. See documentation for variable formats.
- The variable hema_subtype has been dropped.
- New SCU Complications variable indicating whether or not a complication was added from the SCU data.
- Hematopoietic Non-target Misc Cancers:
- Cancers with ICD codes classified as Non-Hodgkins Lymphoma, myeloproliferative disease, or myelodysplastic syndrome have been improved by classifying them as confirmed borderline hematopoietic cancers.
New PLCO ancillary study data added:
New PLCO lab data added:
The total PLCO population now has 154,898 participants. Over the course of the trial this number decreases due to participants withdrawing, improper consent at randomization or duplication at randomization.
New PLCO cancer data added. Data version: may13.d051713
- Biliary Cancer was identified as a cancer of interest. A new dataset is included for biliary cancer. The biliary dataset has the same structure as the existing cancer of interest datasets with the addition of variables bili_type and bili_type2nd, describing the specific nature of the biliary cancer.
- Added to all cancer datasets:
- dcf_unddeath_ccode - What is Cause of Death Cancer Code from Death Certificate?
- f_unddeath_ccode - What is Final Underlying Cause of Death Cancer Code? These provide the 3 digit cancer code to describe cancers for which an ICD code has not yet been determined (e.g. reported cancers not yet confirmed).
- Added to UPGI (upper GI) dataset (differentiates between stomach and esophagus):
- dcf_dthupgi - Is UPGI Cancer The Underlying Cause Of Death (From The Death Certificate)?
- f_dthupgi - Is UPGI Cancer The Underlying Cause Of Death?
- Added to the endoscopy dataset (advanced):
- de_prompt - Was the DEC prompted by a positive screen or by a cancer diagnosis?
- screen_fsg - Was the Endoscopy a Screening FSG?
- Larynx was added to the definition of head-and-neck cancer.
- Colon tumor location variables were renamed :
- colo_tumrloc_side becomes colon_location_side
- colo_tumrloc_summary becomes colon_location_summary
- Colon tumor location variables no longer tablulate insitu colon cancers
New PLCO questionnaire data added:
New PLCO ancillary study data added:
New PLCO lab data added:
The total PLCO population now has 154,898 participants. Over the course of the trial this number decreases due to participants withdrawing, improper consent at randomization or duplication at randomization.